Ravi A. Madan, M.D.

For patients with early recurrent disease defined by a rising PSA after surgery or radiation (often called biochemical recurrence) the focus of Dr. Madan's research program is to extend this potentially indolent phase with out suppressing systemic testosterone levels. Dr. Madan has explored multiple immune strategies, anti-androgen strategies without androgen deprivation, and radiopharmaceuticals in this setting. The emphasis of the trials in this setting is to delay the need for androgen suppression, while maintaining quality of life with treatments that are associated with minimal if any toxicity.

Dr. Madan is exploring the role of PET imaging in recurrent prostate cancer by defining the natural history of the disease in this setting. This approach will help better understand the need for therapy in patients with otherwise negative CT or Tc99 bone scan. Future trials will use AI (artificial intelligence) to better target areas of aggressive cancer within prostate cancer patients.

While immune checkpoint inhibitors are rarely effective in prostate cancer, Dr. Madan is investigating other immunotherapy strategies in the clinic. This includes the use of immunocytokines to impact the broader tumor immune microenvironment beyond just T-cells. The goal here is to deliver immunotherapy in a targeted manner that maximized immune impact while minimizing systemic toxicities. Dr. Madan has several trials ongoing in many stages of prostate cancer with immunocytokines.

Dr. Madan is a Senior Clinician at the National Cancer Institute (NCI), conducting clinical research in prostate cancer with a focus on immunotherapy strategies. Dr. Madan received his M.D. from the Rutgers-New Jersey Medical School in 2001 and completed his internal medicine residency at Rutgers-University Hospital in June 2004. He joined the NCI Medical Oncology Branch as an oncology/hematology fellow in 2005. In 2009 he was appointed to the position of Assistant Clinical Investigator. In 2014 he was made the Clinical Director of the Genitourinary Malignancies Branch and in 2018 he was appointed to the role of Senior Clinician. He holds a joint appointment in the Center for Immuno-Oncology which forms the basis for many of his clinical collaborations. He also works closely with the Molecular Imaging Branch working to better define the role of PSMA imaging in prostate cancer.

Dr. Madan serves on many international review and research committees, including for organizations like the Veteran's Association and Prostate Cancer UK. He also currently serves as the Chair of the FDA's Oncologic Drugs Advisor Committee (ODAC).